Shield Therapeutics PLC Patient Access Expands for Accrufer(R) (7985V)
16 Diciembre 2021 - 12:59AM
UK Regulatory
TIDMSTX
RNS Number : 7985V
Shield Therapeutics PLC
16 December 2021
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Patient Access Expands for Accrufer(R)
Agreements reached with multiple payers giving access to US
commercially insured patients
London, UK, 16 December 2021: Shield Therapeutics plc (LSE:
STX), a commercial stage pharmaceutical company with a focus on
addressing iron deficiency with its lead product Accrufer
(R)/Feraccru(R) (ferric maltol) , announces a progress update on
payer coverage of Accrufer (R) in the US.
Following the US launch of Accrufer(R) in July 2021, one of the
Company's key focus points was to establish payer coverage. Shield
has made substantial progress, successfully securing payer coverage
with several large pharmacy benefit managers (PBMs), including
Express Scripts and Optum, providing the Company with access to
approximately 40 million commercial patients. These contracts
result in Accrufer(R) being placed on formulary (1) and are
effective immediately.
Shield will provide a further, more detailed business update to
shareholders in the first quarter of 2022.
Greg Madison, CEO of Shield, said: "We have made significant
progress over the past few months in the US, by securing
reimbursement for Accrufer(R) among several large pharmacy benefit
managers. Gaining coverage of Accrufer(R) among payers is a
critical step for adoption, and we expect to further expand that
coverage in 2022. Our clinical message has been well received
during the initial stages of our launch, and we continue to expand
awareness of Accrufer(R) among health care professionals."
(1) - Formulary: Is a continually updated list of prescription
drugs approved for reimbursement by the PBMs payer client.
For further information, please contact:
Shield Therapeutics plc +44 (0) 191 511 8500
Greg Madison, CEO
Hans-Peter Rudolf, CFO
Peel Hunt LLP - Nominated Adviser & Joint
Broker +44 (0) 20 7148 8900
James Steel / Christopher Golden
finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Alice Lane/ George Dollemore
Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Applegarth / or shield@walbrookpr.com
Alice Woodings
About Shield
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product
Accrufer(R) / Feraccru(R) (ferric maltol), a novel, stable,
non-salt based oral therapy for adults with iron deficiency with or
without anaemia.
Shield's lead product, Accrufer(R) / Feraccru(R), has been
approved for use in the United States, European Union, UK,
Switzerland and Australia and has exclusive IP rights until the
mid-2030s. The Group has recently launched Accrufer (R) in the US
and Feraccru(R) is already being commercialised in the UK and
European Union by Norgine B.V., who also have the marketing rights
in Australia and New Zealand. Shield also has an exclusive licence
agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialisation of Accrufer(R) / Feraccru (R) in
China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCQELFFFLLEFBE
(END) Dow Jones Newswires
December 16, 2021 01:59 ET (06:59 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024